PREVALENCE OF ANEMIA AND LABORATORY ALTERATIONS IN PATIENTS WITH CHRONIC KIDNEY DISEASE

R.Z. Umurzaqova; M.M. Xakimova

PREVALENCE OF ANEMIA AND LABORATORY ALTERATIONS IN PATIENTS WITH CHRONIC KIDNEY DISEASE

R.Z. Umurzaqova

Associate Professor, PhD

M.M. Xakimova

Master’s Student, 1st Year, Laboratory Work) Department of Hospital Therapy and Endocrinology, Andijan State Medical Institute, Andijan, Uzbekistan.

##semicolon## Chronic kidney disease, renal anemia, erythropoietin, glomerular filtration rate, hemoglobin, iron deficiency, ferritin.

सार

Anemia is a widespread and severe complication of Chronic Kidney Disease (CKD) that significantly accelerates cardiovascular morbidity and reduces the quality of life. This study aims to evaluate the prevalence of anemia and specific laboratory alterations in patients with varying stages of CKD. A retrospective, cross-sectional study was conducted involving 90 patients with CKD stages 3 to 5 and a control group of 30 healthy individuals. Comprehensive laboratory analyses, including complete blood counts, iron profiles (ferritin, transferrin saturation), and estimated glomerular filtration rate (eGFR), were performed. Statistical evaluation utilized the Student’s t-test and chi-square test. The results demonstrated a clear inverse correlation between renal function and hemoglobin levels. Anemia was present in 45% of Stage 3, 78% of Stage 4, and 95% of Stage 5 CKD patients. Hemoglobin levels significantly decreased from 135 ± 12 g/L in the control group to 88 ± 8.5 g/L in Stage 5 CKD patients (p < 0.001). Furthermore, functional iron deficiency, characterized by normal or elevated ferritin (315 ± 42 mcg/L) but low transferrin saturation (18 ± 3%), was observed in 62% of the advanced CKD cohort. The study concludes that anemia in CKD is multifactorial, driven not only by erythropoietin deficiency but also by impaired iron metabolism and systemic inflammation. Early laboratory screening and targeted therapeutic interventions are critical to managing this complication and preventing adverse cardiovascular outcomes.

##submission.citations##

1. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. (2012). KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney International Supplements, 2(4), 279-335. DOI: 10.1038/kisup.2012.37

2. Babitt, J. L., & Lin, H. Y. (2021). Mechanisms of anemia in CKD. Journal of the American Society of Nephrology, 32(11), 2715-2722. DOI: 10.1681/ASN.2021060830

3. Portolés, J., Martín, L., Broseta, J. J., & Cases, A. (2021). Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. Frontiers in Medicine, 8, 642296. DOI: 10.3389/fmed.2021.642296

4. Stauffer, M. E., & Fan, T. (2020). Prevalence of anemia in chronic kidney disease in the United States. PLoS One, 9(1), e84943. DOI: 10.1371/journal.pone.0084943

5. Gafter-Gvili, A., Schechter, A., & Rozen-Zvi, B. (2019). Iron deficiency anemia in chronic kidney disease. Acta Haematologica, 142(1), 44-50. DOI: 10.1159/000496492

6. Fishbane, S., & Spinowitz, B. (2018). Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018. American Journal of Kidney Diseases, 71(3), 423-435. DOI: 10.1053/j.ajkd.2017.09.026

7. Mikhail, A., Brown, C., Williams, J. A., Mathrani, V., Shrivastava, R., & Evans, J. (2017). Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrology, 18(1), 345. DOI: 10.1186/s12882-017-0688-1